<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750577</url>
  </required_header>
  <id_info>
    <org_study_id>1366-0005</org_study_id>
    <secondary_id>2020-002929-28</secondary_id>
    <nct_id>NCT04750577</nct_id>
  </id_info>
  <brief_title>A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease</brief_title>
  <official_title>Randomised, Double-blind (Within Dose Groups), Placebo-controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Diabetic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to adults with diabetic kidney disease. The purpose of the study is to&#xD;
      find out whether a medicine called BI 685509 improves kidney function. Three different doses&#xD;
      of BI 685509 are tested in this study.&#xD;
&#xD;
      Participants get either one of the three doses of BI 685509 or placebo. It is decided by&#xD;
      chance who gets which BI 685509 dose and who gets placebo. Participants take BI 685509 or&#xD;
      placebo as tablets 3 times a day. Placebo tablets look like BI 685509 tablets but do not&#xD;
      contain any medicine. Participants continue taking their usual medicine for diabetes and&#xD;
      kidney disease throughout the study.&#xD;
&#xD;
      Participants are in the study for about 7 months. During this time, they visit the study site&#xD;
      about 11 times. Where possible, about 6 of the 11 visits can be done at the participant's&#xD;
      home instead of the study site. The trial staff may also contact the participants by phone or&#xD;
      video call.&#xD;
&#xD;
      Kidney function is assessed based on the analysis of urine samples, which participants&#xD;
      collect at home. At the end of the trial the results are compared between the different doses&#xD;
      of BI 685509 and placebo. During the study, the doctors also regularly check the general&#xD;
      health of the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">August 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 19, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre, randomised, double-blind (within dose groups), parallel, placebo-controlled trial. Patients will be randomised equally into one of three parallel dose groups, and in each dose group to treatment either with BI 685509 or matching placebo in a 3:1 ratio.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in log transformed Urine Albumin Creatinine Ratio (UACR) measured in 10-hour urine after 20 weeks of trial treatment</measure>
    <time_frame>Up to 20 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in log transformed UACR measured in First Morning Void urine after 20 weeks of trial treatment</measure>
    <time_frame>Up to 20 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving UACR decreases in 10-hour urine of at least 20% from baseline after 20 weeks of trial treatment</measure>
    <time_frame>Up to 20 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving UACR decreases in First Morning Void urine of at least 20% form baseline after 20 weeks of trial treatment</measure>
    <time_frame>Up to 20 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Dose group 1: BI 685509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 1: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for low dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2: BI 685509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose followed by up-titration to medium dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for low dose followed by up-titration to medium dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3: BI 685509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose followed by up-titration to medium dose, followed by up-titration to high-dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for low dose followed by up-titration to medium dose, followed by up-titration to high dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Dose group 1: Matching placebo</arm_group_label>
    <arm_group_label>Dose group 2: Matching placebo</arm_group_label>
    <arm_group_label>Dose group 3: Matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 685509</intervention_name>
    <description>BI 685509</description>
    <arm_group_label>Dose group 1: BI 685509</arm_group_label>
    <arm_group_label>Dose group 2: BI 685509</arm_group_label>
    <arm_group_label>Dose group 3: BI 685509</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Signed and dated written informed consent in accordance with International Council of&#xD;
             Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to&#xD;
             admission to the trial.&#xD;
&#xD;
          2. Male or female patients aged ≥ 18 years at time of consent.&#xD;
&#xD;
          3. eGFR (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) ≥ 20 and &lt;&#xD;
             90 mL/min/1.73 m2 at Visit 1 by central laboratory analysis. eGFR must remain ≥ 20&#xD;
             mL/min/1.73 m2 after Visit 1 up to the start of Visit 3, measured by central or any&#xD;
             local laboratory analysis.&#xD;
&#xD;
          4. Urine Albumin Creatinine Ratio (UACR) ≥ 200 and &lt; 3,500 mg/g in spot urine (midstream&#xD;
             urine sample) by central laboratory analysis at Visit 1.&#xD;
&#xD;
          5. Treatment with the highest tolerated dose of either Angiotensin Converting Enzyme&#xD;
             inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) (but not both together), and&#xD;
             stable dose for ≥ 4 weeks before Visit 1 with no planned change of the therapy during&#xD;
             the trial.&#xD;
&#xD;
          6. If the patient is taking any of the following medications they should be on a stable&#xD;
             dose at least 4 weeks prior to visit 1 until start of treatment, with no planned&#xD;
             change of the therapy during the trial: anti-hypertensives, Non-steroidal&#xD;
             anti-inflammatory drug(s) (NSAIDs), endothelin receptor antagonists, systemic steroids&#xD;
             or Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors.&#xD;
&#xD;
          7. Patients with stable type 1 or type 2 diabetes mellitus, diagnosed before informed&#xD;
             consent. Treatment (including SGLT2 inhibitor and/or Glucagon-Like Peptide 1 (GLP1)&#xD;
             receptor agonist) should have been unchanged or changes deemed minor (according to&#xD;
             investigator's judgement) within 4 weeks before Visit 1 and until start of trial&#xD;
             treatment.&#xD;
&#xD;
          8. Glycated Haemoglobin (HbA1c) &lt; 10.0% at Visit 1 measured by the central laboratory.&#xD;
&#xD;
        Furhter inclusion criteria apply.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Treatment with Renin Angiotensin Aldosterone System (RAAS) interventions (apart from&#xD;
             either ACEi or ARB), phosphodiesterase inhibitors, nitrates,&#xD;
             sGC-stimulators/activators (other than trial treatment) or any other restricted&#xD;
             medication (including Organic Anion-Transporting Polypeptide 1B1 and 1B3 (OATP1B1/3)&#xD;
             inhibitors, Uridine 5'-diphosphate -glucuronosyltransferase (UGT) inhibitors/inducers)&#xD;
             as provided in the Investigator Site File (ISF) within 4 weeks prior to visit 1 and&#xD;
             throughout screening and baseline run-in. Patients who must or wish to continue the&#xD;
             intake of restricted medications or any drug considered likely to interfere with the&#xD;
             safe conduct of the trial are also excluded.&#xD;
&#xD;
          2. Any clinically relevant laboratory value from screening until start of trial&#xD;
             treatment, which in the investigator's judgement puts the patient at additional risk.&#xD;
&#xD;
          3. Biopsy or otherwise confirmed non-diabetic chronic kidney disease, or non-diabetic&#xD;
             chronic kidney disease in the opinion of investigator, e.g., Autosomal Dominant&#xD;
             Polycystic Kidney Disease (ADPKD), uncontrolled lupus nephritis. The presence of a&#xD;
             hypertensive etiology does not need to be excluded unless it is evident this is the&#xD;
             only cause for the Chronic Kidney Disease (CKD).&#xD;
&#xD;
          4. Any immunosuppression therapy or immunotherapy in the last 3 months prior to visit 1&#xD;
             and throughout screening and baseline run-in (except prednisolone ≤10 mg or&#xD;
             equivalent).&#xD;
&#xD;
          5. Acute kidney injury (AKI) according to the Kidney Disease: Improving Global Outcomes&#xD;
             (KDIGO) in the 30 days prior to Visit 1 until the start of trial treatment.&#xD;
&#xD;
          6. Planned start of chronic renal replacement therapy during the trial or end stage renal&#xD;
             disease before start of trial treatment.&#xD;
&#xD;
          7. Known history of moderate or severe symptomatic orthostatic dysregulation as judged by&#xD;
             the investigator before start of trial treatment.&#xD;
&#xD;
          8. The patient has an active infection with Severe Acute Respiratory Syndrome Coronavirus&#xD;
             2 (SARS-CoV-2) (or is known to have a positive test) from screening until&#xD;
             randomisation.&#xD;
&#xD;
        Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Riverside Nephrology Physicians</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Khan</last_name>
      <phone>+001(800)797-1695</phone>
      <email>mkhan@nariresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kidney and Hypertension Center</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgard Vera Tapia</last_name>
      <phone>+001(760)245-2760</phone>
      <email>edgardvera@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sina Raissi</last_name>
      <phone>+001(203)758-1800</phone>
      <email>sinaraissi@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Soufer</last_name>
      <phone>+001(203)419-4420</phone>
      <email>jsoufer@chasemr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Cardona</last_name>
      <phone>+001(305)825-6588</phone>
      <email>jcardona@indagoresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panax Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Perry</last_name>
      <phone>+001(305)698-4500</phone>
      <email>rperry@panaxcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanson Clinical Research Center, Inc.</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lenita Hanson</last_name>
      <phone>+001(941)875-3053</phone>
      <email>lhansonmd@hansoncrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinayak Ramanath</last_name>
      <phone>+001(706)593-2127</phone>
      <email>vramanath79@googlemail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Bradley</last_name>
      <phone>+001(912)443-4253</phone>
      <email>pbradley@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research by Design, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Crawford</last_name>
      <phone>+001(708)952-3040</phone>
      <email>pcrawford@researchbd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Harper</last_name>
      <phone>+001(402)371-0797</phone>
      <email>charper@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Vishnepolsky</last_name>
      <phone>+001(614)330-6674</phone>
      <email>mvishnepolsky@ksosn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Total Renal Research</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Lynn</last_name>
      <phone>+001(718)708-7845</phone>
      <email>rlynn@kidneymedical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brookview Hills Research Associates LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Greenwood</last_name>
      <phone>+001(877)330-2919</phone>
      <email>greenwood.gregory@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Knoxville Kidney Center PLLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Hendon</last_name>
      <phone>+001(865)692-3462</phone>
      <email>kendra_hendon@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Olivero</last_name>
      <phone>+001(713)292-0619</phone>
      <email>jolivero2@houstonkidney.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Institute for Kidney and Endocrine Disorders</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lance Sloan</last_name>
      <phone>+001(936)414-3636</phone>
      <email>tikedlufkin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Advancement Center, PLLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Pergola</last_name>
      <phone>+001(210)223-4444</phone>
      <email>ppergola@raparesearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sayed Tabatabai</last_name>
      <phone>+001(210)495-8280</phone>
      <email>stabatabai@sakidney.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kidney Specialists of North Houston, PLLC</name>
      <address>
        <city>Shenandoah</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Frome</last_name>
      <phone>+001(936)273-0836</phone>
      <email>afrome18@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tidewater Kidney Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiranjit Dhillon</last_name>
      <phone>+001(757)623-0005</phone>
      <email>KDhillon@tksva.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEDIC - Centro de Investigacion Clinica</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Gelersztein</last_name>
      <phone>+54114826-1208</phone>
      <email>elizabeth.g@cedic-argentina.com.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Especializado</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Castaño</last_name>
      <phone>541149039777</phone>
      <email>patriciacasta4@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Médico Viamonte</name>
      <address>
        <city>Ciudad Autonoma de Bs As</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Aizenberg</last_name>
      <phone>+541149635650</phone>
      <email>diegoaiz@fibertel.com.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inst. Privado de Inv. Clínicas de Córdoba</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Pautasso</last_name>
      <phone>+543514630065</phone>
      <email>mjpautasso@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Médicas</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Alvarisqueta</last_name>
      <phone>+542234917628</phone>
      <email>andres.alvarisqueta@cimmdp.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Catamarca - IMEC</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha Maldonado</last_name>
      <phone>+543412985581</phone>
      <email>natachamaldonado@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEREHA S.A.- Centro de Estudios Renales e Hipertensión Art</name>
      <address>
        <city>Sarandi</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Elbert</last_name>
      <phone>+54114217-0963</phone>
      <email>alicia.elbert.nd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renal Research, Gosford</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Roger</last_name>
      <phone>+61243237977</phone>
      <email>simon@renalresearch.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muralikrishna Komala</last_name>
      <phone>+61247344355</phone>
      <email>Muralikrishna.Gangadharankomala@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Champion</last_name>
      <phone>+61298122976</phone>
      <email>bernard.champion@mq.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Pollock</last_name>
      <phone>+610299264652</phone>
      <email>carol.pollock@sydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Lee</last_name>
      <phone>+61288906962</phone>
      <email>vincent_lee@wmi.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elif Ekinci</last_name>
      <phone>61394962250</phone>
      <email>elif.ekinci@unimelb.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Tan</last_name>
      <phone>+61393427053</phone>
      <email>Jean.Tan@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CARe Clinic</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josias Badenhorst</last_name>
      <phone>589-815-0803</phone>
      <email>josias@careclinicrd.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albion Finch Medical Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Gupta</last_name>
      <phone>416-741-1500</phone>
      <email>drgupta106@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fadia El Boreky Medicine Professional</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadia El Boreky</last_name>
      <phone>519-569-7592</phone>
      <email>fadiaboreky@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minghui Zhao</last_name>
      <phone>13501243815</phone>
      <email>Zhaomh20212021@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lian He</last_name>
      <phone>13391760656</phone>
      <email>ducklianhe@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohui Liao</last_name>
      <phone>13594350439</phone>
      <email>1263201771@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sjællands Universitetshospital</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rikke Borg</last_name>
      <phone>+4593566535</phone>
      <email>rbor@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea LUK</last_name>
      <phone>(852)35051641</phone>
      <email>andrealuk@cuhk.edu.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi Wai TANG</last_name>
      <phone>(852)22553603</phone>
      <email>scwtang@hku.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chubu Rosai Hospital</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiro Fujita</last_name>
      <phone>+81526525511</phone>
      <email>Yoshiro.F.M.D@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daido Hospital</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideaki Shimizu</last_name>
      <phone>+81526116261</phone>
      <email>daido_shimizu1@yahoo.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka, Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kei Fukami</last_name>
      <phone>+81942353311</phone>
      <email>fukami@med.kurume-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nakayamadera Imai Clinic</name>
      <address>
        <city>Hyogo, Takarazuka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enyu Imai</last_name>
      <phone>+81797862600</phone>
      <email>ADS12069@nifty.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Takai Naika Clinic</name>
      <address>
        <city>Kanagawa, Kamakura</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahiko Takai</last_name>
      <phone>+81467435556</phone>
      <email>chiken5556@yahoo.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kawasaki Medical School Hospital</name>
      <address>
        <city>Okayama, Kurashiki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hajime Nagasu</last_name>
      <phone>+8186462-1111</phone>
      <email>HajimeNagasu@kms-ndh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terumasa Hayashi</last_name>
      <phone>+81666921201</phone>
      <email>t-hayashi@abelia.ocn.ne.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OCROM Clinic</name>
      <address>
        <city>Osaka, Suita</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoshi Inoue</last_name>
      <phone>+81663308810</phone>
      <email>satoshi.inoue@heishinkai.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Hospital</name>
      <address>
        <city>Saitama, Iruma-gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirokazu Okada</last_name>
      <phone>+81492761111</phone>
      <email>hirookda@saitama-med.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo, Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Nishi</last_name>
      <phone>+81338155411</phone>
      <email>hrnishi-tky@g.ecc.u-tokyo.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arihiro Kiyosue</last_name>
      <phone>+81335176688</phone>
      <email>arihiro.kiyosue@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ToCROM Clinic</name>
      <address>
        <city>Tokyo, Shinjyuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osamu Matsuoka</last_name>
      <phone>+81353665333</phone>
      <email>osamu.matsuoka@heishinkai.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Kebangsaan Malaysia</name>
      <address>
        <city>Cheras, Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdul Halim Abdul Gafor</last_name>
      <phone>603-91702108</phone>
      <email>halimgafor@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Kun Lim</last_name>
      <email>limsk@ummc.edu.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hin Seng Wong</last_name>
      <phone>0060361263333</phone>
      <email>hinseng@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Cardiologica Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Llamas Esperon</last_name>
      <phone>+524499155648,+524499154000</phone>
      <email>galle@cardiologica.com.mx</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albert SchweitzerZiekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen van der Net</last_name>
      <phone>+31786542886</phone>
      <email>j.b.vandernet@asz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>GA Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold de Valk</last_name>
      <phone>+31887555161</phone>
      <email>H.W.deValk@umcutrecht.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bethesda Diabetes Research Center, Hoogeveen</name>
      <address>
        <city>RA Hoogeveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriaan Kooy</last_name>
      <phone>+31528286859</phone>
      <email>a.kooy@treant.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Walker</last_name>
      <phone>+6434740999</phone>
      <email>rob.walker@otago.ac.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research Kapiti</name>
      <address>
        <city>Paraparaumu</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Pointing</last_name>
      <phone>6449081001</phone>
      <email>NicolaP@p3research.co.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kingsley Nirmalaraj</last_name>
      <phone>+6475790453</phone>
      <email>Kingsley.Nirmalaraj@bopdhb.govt.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IndividualProfessional Medical Practice</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Grzybowski</last_name>
      <phone>+48585357196,+48607442725</phone>
      <email>agrzybowski@uck.gda.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicome Limited Liability Company</name>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwona Kobielusz-Gembala</last_name>
      <phone>+48604517177</phone>
      <email>iwonagembala@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Soto González</last_name>
      <phone>+34981178127</phone>
      <email>asotog10@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María José Soler</last_name>
      <phone>+34934893000ext.4872</phone>
      <email>m.soler@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristobal Morales Portillo</last_name>
      <phone>+34600162406</phone>
      <email>cr.morales@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Gorriz Teruel</last_name>
      <phone>+34961973811</phone>
      <email>jlgorriz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harpal Randeva</last_name>
      <phone>02476964000</phone>
      <email>harpal.randeva@uhcw.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barts and The London School of Medicine and Dentistry</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Saxena</last_name>
      <phone>+442078825657</phone>
      <email>m.saxena@qmul.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

